---
figid: PMC9540797__VCO-20-602-g006
pmcid: PMC9540797
image_filename: VCO-20-602-g006.jpg
figure_link: /pmc/articles/PMC9540797/figure/vco12813-fig-0006/
number: FIGURE 6
figure_title: ''
caption: Tumour responses to IL‐2/CD40. The percentage change in tumour size over
  time (A) in individual dogs with progressive disease (red), stable disease (green)
  and partial responses (blue) shown as a spider plot. The waterfall plot (B) (n = 19)
  shows individual responses to doses 4 (blue), 5 (red) and 6 (purple), plus the other
  doses combined (black) at 1 month, tumour reduction includes 50% or greater tumour
  decrease and <25% increase). Changes to tumour size in dogs with partial remission
  shown as a spider plot (C), starting sizes shown at day 0
article_title: Developing a translational murine‐to‐canine pathway for an IL‐2/agonist
  anti‐CD40 antibody cancer immunotherapy.
citation: Stephen Francis Proksch, et al. Vet Comp Oncol. 2022 Sep;20(3):602-612.
year: '2022'

doi: 10.1111/vco.12813
journal_title: Veterinary and Comparative Oncology
journal_nlm_ta: Vet Comp Oncol
publisher_name: Blackwell Publishing Ltd

keywords:
- anti‐CD40 antibody
- dogs
- immunotherapy
- interleukin‐2
- soft tissue sarcoma

---
